Follow-On Offering

Healthcare
Follow-On Offering

Summary

Baird served as co-manager on this offering.

About

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) recently completed a follow-on offering of 5,479,750 shares of common stock at $21.00 per share, generating gross proceeds of approximately $115.1 million. The Company intends to use the net proceeds from the offering for general corporate purposes.

Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. The Company’s pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), the Company’s first commercial product, is a once-daily dual-mechanism antibiotic approved in the United States, Europe and certain other countries for certain difficult-to-treat infections. Theravance Biopharma’s United States operating subsidiary is located in San Francisco, California.

For additional information about this transaction, please contact:

Ryan Mausehund +1 (650) 858-3817
Lance Lange +1 (414) 765-7079
Vincenzo di Nicola +44 (207) 667-8352
Anthony Siu +86 (21) 618-20980
Healthcare
Follow-On Offering
Date
June 2016
Company
Theravance Biopharma, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America
Acquiror Location
North America

Share